Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up)

[1]  Y. Ohya,et al.  A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis , 2021, JAAD international.

[2]  J. Silverberg,et al.  Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial , 2021, The Lancet.

[3]  A. Paller,et al.  Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials , 2021, The Lancet.

[4]  S. Langan,et al.  Atopic dermatitis , 2020, The Lancet.

[5]  Y. Ohya,et al.  Japanese guidelines for atopic dermatitis 2020. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[6]  C. Scholtysek,et al.  JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function , 2020, Science Translational Medicine.

[7]  Toshiaki Tanaka,et al.  Reduced pubertal growth in children with obesity regardless of pubertal timing. , 2020, Endocrine journal.

[8]  D. Margolis,et al.  Pain is a common and burdensome symptom of atopic dermatitis in United States adults. , 2019, The journal of allergy and clinical immunology. In practice.

[9]  F. Gómez-García,et al.  Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata , 2019, Dermatology and Therapy.

[10]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  J. Silverberg,et al.  Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  T. Agner,et al.  Quality of life and disease severity in patients with atopic dermatitis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  Yoshiya Ito,et al.  Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey , 2016, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[14]  C. Bindslev‐Jensen,et al.  Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities , 2015, Allergy. European Journal of Allergy and Clinical Immunology.

[15]  J. Silverberg,et al.  Association between eczema and stature in 9 US population-based studies. , 2015, JAMA dermatology.

[16]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. , 2014, Journal of the American Academy of Dermatology.

[17]  S. Takeuchi,et al.  Epidemiology of atopic dermatitis in Japan , 2014, The Journal of dermatology.

[18]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[19]  J. Silverberg,et al.  Association between obesity and atopic dermatitis in childhood: a case-control study. , 2011, The Journal of allergy and clinical immunology.

[20]  T. Bieber.  Atopic dermatitis. , 2010, Annals of dermatology.

[21]  T. Sørensen,et al.  Age at Puberty and the Emerging Obesity Epidemic , 2009, PloS one.

[22]  P. Daley-Yates,et al.  Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. , 2004, Clinical therapeutics.

[23]  R. Olney.  Regulation of bone mass by growth hormone. , 2003, Medical and pediatric oncology.

[24]  S. Ahmed,et al.  Short‐term effects on linear growth and bone turnover in children randomized to receive prednisolone or dexamethasone , 2002, Clinical endocrinology.

[25]  J. Herrington,et al.  Role of the tyrosine kinase JAK2 in signal transduction by growth hormone , 2000, Pediatric Nephrology.

[26]  E. Graham,et al.  Systemic corticosteroid therapy—side effects and their management , 1998, The British journal of ophthalmology.

[27]  K. Tachibana,et al.  Longitudinal Standards for Height and Height Velocity for Japanese Children from Birth to Maturity , 1992 .